Guardant Health, Inc. (NASDAQ:GH) Position Boosted by Handelsbanken Fonder AB

Handelsbanken Fonder AB grew its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 31.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 161,341 shares of the company’s stock after purchasing an additional 38,900 shares during the period. Handelsbanken Fonder AB owned approximately 0.14% of Guardant Health worth $4,364,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in GH. abrdn plc acquired a new position in shares of Guardant Health in the fourth quarter worth about $9,362,000. Knights of Columbus Asset Advisors LLC boosted its holdings in shares of Guardant Health by 108.1% in the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 79,026 shares of the company’s stock worth $2,138,000 after buying an additional 41,059 shares during the period. Strs Ohio boosted its holdings in shares of Guardant Health by 19.0% in the fourth quarter. Strs Ohio now owns 23,800 shares of the company’s stock worth $643,000 after buying an additional 3,800 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Guardant Health by 207.4% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 343,745 shares of the company’s stock worth $9,298,000 after buying an additional 231,904 shares during the period. Finally, Cerity Partners LLC boosted its holdings in shares of Guardant Health by 225.4% in the fourth quarter. Cerity Partners LLC now owns 49,642 shares of the company’s stock worth $1,343,000 after buying an additional 34,388 shares during the period. Institutional investors own 92.60% of the company’s stock.

Insider Buying and Selling

In other Guardant Health news, insider Kumud Kalia purchased 2,187 shares of the firm’s stock in a transaction on Monday, March 18th. The shares were purchased at an average price of $17.82 per share, for a total transaction of $38,972.34. Following the completion of the purchase, the insider now directly owns 12,722 shares of the company’s stock, valued at $226,706.04. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.20% of the stock is currently owned by insiders.

Guardant Health Stock Performance

NASDAQ:GH opened at $17.16 on Friday. Guardant Health, Inc. has a 12 month low of $15.81 and a 12 month high of $41.06. The company has a debt-to-equity ratio of 7.18, a current ratio of 6.54 and a quick ratio of 6.24. The company’s 50 day moving average is $18.94 and its 200-day moving average is $23.00.

Guardant Health (NASDAQ:GH) last announced its earnings results on Thursday, February 22nd. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.65). Guardant Health had a negative return on equity of 301.94% and a negative net margin of 85.02%. The company had revenue of $155.05 million for the quarter, compared to the consensus estimate of $151.71 million. On average, equities research analysts predict that Guardant Health, Inc. will post -3.49 earnings per share for the current year.

Wall Street Analyst Weigh In

GH has been the subject of several research reports. The Goldman Sachs Group decreased their price target on shares of Guardant Health from $32.00 to $28.00 and set a “buy” rating for the company in a report on Monday, April 15th. Guggenheim restated a “neutral” rating on shares of Guardant Health in a report on Friday, April 5th. Craig Hallum started coverage on shares of Guardant Health in a research report on Wednesday. They set a “buy” rating and a $28.00 price objective on the stock. Canaccord Genuity Group cut their price objective on shares of Guardant Health from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday, February 23rd. Finally, Piper Sandler cut their price objective on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating on the stock in a research report on Monday, February 26th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.27.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.